Moyamoya Disease in China


Moyamoya disease (MMD) was considered to be rare in China. With the tremendous improvement of medical care over the past 30 years, especially with the current universal availability of magnetic resonance imaging (MRI) and digital subtraction angiography (DSA), more MMD has been diagnosed. Data concerning its pathophysiological features, clinical presentation, and treatment have been reviewed. The ethnical difference between Chinese and Japanese or Korean seemed not be so large as previously believed [1].


Vascular Endothelial Growth Factor Hepatocyte Growth Factor Digital Subtraction Angiography Moyamoya Disease Middle Meningeal Artery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Matsushima Y, Qian L, Aoyagi M (1997) Comparison of moyamoya disease in Japan and moyamoya disease (or syndrome) in the People's Republic of China. Clin Neurol Neurosurg 99 Suppl 2:s19–s22PubMedCrossRefGoogle Scholar
  2. 2.
    Li B, Wang ZC, Zhao JZ et al (1990) Extracarotid angiography and ultrastructure study in moyamoya. Chin J Neurosurg 6(3):173–175Google Scholar
  3. 3.
    Wang Y, Zeng W, Xue XP et al (2003) Wegener granulomatosis accompanied with cerebral infarction and moyamoya. Case report. Chin J Rbeumatol 7(10):647Google Scholar
  4. 4.
    Zhang HO, Rao ML, Zhang SQ et al (2001) An experimental study on the pathogenic role of immune complex to moyamoya disease. Chin J Neuroimmunol Neuro 13(2):121–123Google Scholar
  5. 5.
    Zhang Y, Meng GL, Zhao JZ et al (2003) The role of basic fibroblast growth factors in the pathogenesis of moyamoya disease. Chin J Nerv Ment Dis 29(1):39–41Google Scholar
  6. 6.
    Jin H, Zou LP, Duan L et a1 (2007) The roles of HGF in the pathogenesis of moyamoya disease. J Apoplexy Nerv Dis 24(2):150–153Google Scholar
  7. 7.
    Xin Y, Zhao JZ et al (2005) Changes of the serum level of vascular endothelial growth factor and transforming growth factor β 1 in patients with moyamoya disease. Beijin Med 27(6):321–323Google Scholar
  8. 8.
    Duan L, Sun WJ, Wang FY et al (2005) Analysis of clinical features in Chinese patients with moyamoya disease. Chin J Clin Neurosurg 10(4):269–272Google Scholar
  9. 9.
    Sien TC, Yang HL, Chung YH et al (1988) Moyamoya disease in Taiwan. Stroke 19:53–59CrossRefGoogle Scholar
  10. 10.
    Wang ZC (1994) Cerebral vascular diseases and surgical treatment. Beijing: Beijing publishing company l80–195Google Scholar
  11. 11.
    Fukui M (1997) Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis (‘moyamoya’ disease). Clin Neurol Neurosurg 99 Suppl 2:S238–S240PubMedGoogle Scholar
  12. 12.
    Gao QY, Li N, Li YM et al (2004) Evaluation of cerebral hemodynamic in moyamoya disease using acetazolamide (Diamox)99mTc-HMPAO SPECT. J Chin Med Univ 33(1):80–82Google Scholar
  13. 13.
    Tang WJ, Fan WJ, Huang XL (1999) DSA analysis of moyamoya disease. J Prac Radio 15(12):720–723Google Scholar
  14. 14.
    Yang MQ, Ni M, Wang S et al (2007) Clinical analysis of the hemorrhagic type moyamoya disease. J Cap Med Univ 28(4):528–531Google Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  1. 1.Department of NeurosurgeryChanghai HospitalShanghaiChina
  2. 2.Department of NeurosurgeryGuangzhou General Hospital of Guangzhou Military Area CommandGuangzhouChina

Personalised recommendations